REGN
REGENERON PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$930.67
−4.39%Jun 1, 2026, 15:35 UTC
Regeneron Pharmaceuticals reported first-quarter earnings that exceeded analyst estimates, driven by strong sales of Dupixent and Eylea HD.
Source:
← PreviousPage 2